<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2018-33-4-90-97</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-616</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>ОЦЕНКА И ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ СИМПАТОВАГАЛЬНОГО СТАТУСА ПАЦИЕНТОВ В ОСТРОМ ПЕРИОДЕ ИНФАРКТА МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST</article-title><trans-title-group xml:lang="en"><trans-title>ESTIMATION AND PROGNOSTIC VALUE OF THE PATIENTS SIMPATOVAGAL STATUS IN THE ACUTE PERIOD OF MYOCARDIAL INFARCT WITH ST SEGMENT ELEVATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олейников</surname><given-names>В. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Oleynikov</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующий кафедрой терапии</p><p>440026, Российская Федерация, Пенза, ул. Красная, 40</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Department of Therapy</p><p>40, Krasnaja str., Penza, 440026, Russian Federation</p></bio><email xlink:type="simple">v.oleynikof@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Душина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dushina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры терапии</p><p>440026, Российская Федерация, Пенза, ул. Красная, 40</p></bio><bio xml:lang="en"><p>MD, Assistant, Department of Therapy</p><p>40, Krasnaja str., Penza, 440026, Russian Federation</p></bio><email xlink:type="simple">dushina-elena@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyanova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры терапии</p><p>440026, Российская Федерация, Пенза, ул. Красная, 40</p></bio><bio xml:lang="en"><p>MD, PhD, Department of Therapy</p><p>40, Krasnaja str., Penza, 440026, Russian Federation</p></bio><email xlink:type="simple">mavlu2002@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барменкова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Barmenkova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры терапии</p><p>440026, Российская Федерация, Пенза, ул. Красная, 40</p></bio><bio xml:lang="en"><p>MD, Assistant, Department of Therapy</p><p>40, Krasnaja str., Penza, 440026, Russian Federation</p></bio><email xlink:type="simple">terapia-pgu@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеева</surname><given-names>И. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseeva</surname><given-names>I. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой общей и клинической фармакологии</p><p>440026, Российская Федерация, Пенза, ул. Красная, 40</p></bio><bio xml:lang="en"><p>MD, PhD, Professor, Head of Department of General and Clinical Pharmacology</p><p>40, Krasnaja str., Penza, 440026, Russian Federation</p></bio><email xlink:type="simple">moiseeva_pharm@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пензенский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Institute, Penza State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2019</year></pub-date><volume>33</volume><issue>4</issue><fpage>90</fpage><lpage>97</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Олейников В.Э., Душина Е.В., Лукьянова М.В., Барменкова Ю.А., Моисеева И.Я., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Олейников В.Э., Душина Е.В., Лукьянова М.В., Барменкова Ю.А., Моисеева И.Я.</copyright-holder><copyright-holder xml:lang="en">Oleynikov V.E., Dushina E.V., Lukyanova M.V., Barmenkova Y.A., Moiseeva I.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/616">https://www.sibjcem.ru/jour/article/view/616</self-uri><abstract><p>Цель: Провести анализ влияния вегетативного статуса регуляции сердечной деятельности в ранние сроки инфаркта миокарда с подъемом сегмента ST на фрагментированную активность, развитие и прогрессирование сердечной недостаточности и отдаленный прогноз пациентов.Материал и методы. В исследование включено 143 человека. Для выявления нормальных значений параметров вариабельности ритма обследовано 54 здоровых добровольца. Группу наблюдения составили 89 больных с инфарктом миокарда с подъемом сегмента ST, которым выполнялось суточное мониторирование ЭКГ на 7–9-е сутки, 24 и 48-й неделях с оценкой вариабельности ритма, поздних потенциалов желудочков. В те же сроки определяли уровень мозгового натрийуретического пептида и высокочувствительного С-реактивного белка. Каждые 12 недель пациенты выполняли тест с 6-минутной ходьбой. В качестве end-point отслеживалось развитие повторных сердечно-сосудистых событий.Результаты. Больные по результатам анализа вариабельности ритма на 7–9-е сутки инфаркта миокарда с подъемом сегмента ST были разделены на группы: группа 1 с нормальным тонусом вариабельности ритма, группа 2 — с повышенными симпатическими влияниями на ритм. В группе 1 регистрировался выраженный регресс уровня мозгового натрийуретического пептида уже к 24-й неделе после инфаркта миокарда с подъемом сегмента ST. Концентрация высокочувствительного С-реактивного белка снизилась во всех группах. Только в группе нормального тонуса вариабельности ритма зафиксирована благоприятная трансформация показателей, отражающих фрагментированную активность миокарда — HFLA и RMS. Риск развития повторных сердечно-сосудистых событий в течение 48 недель инфаркта миокарда с подъемом сегмента ST в группе с доминирующей симпатической активностью был значительно выше, чем в группе нормального вегетативного статуса.Заключение. Гиперсимпатикотония в острый период инфаркта миокарда с подъемом сегмента ST ассоциировалась с повышением относительного риска развитий повторных кардиальных событий и отрицательно отражалась на динамике лабораторных индикаторов развития и прогрессирования хронической сердечной недостаточности. </p></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to analyze the impact of the status of cardiac autonomic nervous regulation on the fragmentation activity, development and progression of heart failure, and the long-term prognosis in patients with early ST segment elevation myocardial infarction.Material and Methods. The study included 143 subjects; 54 healthy volunteers were examined to identify normal values of heart rhythm variability parameters. The observation group comprised 89 patients with ST segment elevation myocardial infarction who underwent 24-hour ECG monitoring at day 7 to 9 as well as at 24 and 48 weeks with follow up assessment of heart rate variability and late ventricular potentials. At the time points, the levels of brain natriuretic peptide and highly sensitive C-reactive protein were determined. Patients underwent a 6-min walk test every 12 weeks. The development of repeated cardiovascular events has been monitored as an end-point. Patients were assigned to two groups according to results of heart rhythm variability analysis at day 7–9 after onset of ST segment elevation myocardial infarction: group 1 had normal heart rate variability; group 2 had increased sympathetic impact on rhythm.Results. In group 1, a pronounced regression of the brain natriuretic peptide level was registered 24 week after onset of ST segment elevation myocardial infarction. The value of C-reactive protein decreased in all groups. A favorable transformation of the indices reflecting the fragmentation activity — high-frequency low-amplitude and root mean square — of the myocardium was recorded only in the group with normal heart rate variability parameters. The risk of repeated cardiovascular events during 48 weeks after ST segment elevation myocardial infarction was significantly higher in the group with dominant sympathetic activity than in the group with normal status of the autonomic nervous system.Conclusion. Hypersympathicotonia in the acute period of ST segment elevation myocardial infarction was associated with an increased relative risk of repeated cardiac events and negatively affected the dynamics of laboratory parameters indicative of heart failure development and progression.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>холтеровское мониторирование ЭКГ</kwd><kwd>вариабельность сердечного ритма</kwd><kwd>поздние потенциалы желудочков</kwd><kwd>высокочувствительный С-реактивный белок</kwd><kwd>мозговой натрийуретический пептид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>holter ECG monitoring</kwd><kwd>heart rate variability</kwd><kwd>late ventricular potentials</kwd><kwd>highly sensitive C-reactive protein</kwd><kwd>brain natriuretic peptide</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Florea V. G., Cohn J. N. The Autonomic Nervous System and Heart Failure. Circulation Research. 2014; 114: 1815–1826.</mixed-citation><mixed-citation xml:lang="en">Florea V. G., Cohn J. N. The Autonomic Nervous System and Heart Failure. Circulation Research. 2014; 114: 1815–1826.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">La Rovere M. T. GISSI-HF Investigators. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: Still a place in prognostication? Data from the GISSI-HF trial. Eur. J. Heart Failure. 2012; 14: 1410–1419.</mixed-citation><mixed-citation xml:lang="en">La Rovere M. T. GISSI-HF Investigators. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: Still a place in prognostication? Data from the GISSI-HF trial. Eur. J. Heart Failure. 2012; 14: 1410–1419.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wellens H. J., Schwartz P. J., Lindemans F. W., Buxton A. E., Goldberger J. J., Hohnloser S. H., Huikuri H. V., Kааb S., La Rovere M. T., Malik M. Risk stratification for sudden cardiac death: Current status and challenges for the future. Eur. Heart J. 2014; 35: 1642–1651.</mixed-citation><mixed-citation xml:lang="en">Wellens H. J., Schwartz P. J., Lindemans F. W., Buxton A. E., Goldberger J. J., Hohnloser S. H., Huikuri H. V., Kааb S., La Rovere M. T., Malik M. Risk stratification for sudden cardiac death: Current status and challenges for the future. Eur. Heart J. 2014; 35: 1642–1651.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of European Society of Cardiology and the North American Society of pacing and Electrophysiology. Circulation. 1996; 93: 1043–1065.</mixed-citation><mixed-citation xml:lang="en">Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of European Society of Cardiology and the North American Society of pacing and Electrophysiology. Circulation. 1996; 93: 1043–1065.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Huikuri H. V., Exner D. V., Kavanagh K. M. CARISMA and REFINE Investigators. Attenuated recovery of heart rate turbulence early after myocardial infarction identifies patients at high risk for fatal or near-fatal arrhythmic events. Heart Rhythm: The Official Journal of the Heart Rhythm Society. 2010; 7: 229–235.</mixed-citation><mixed-citation xml:lang="en">Huikuri H. V., Exner D. V., Kavanagh K. M. CARISMA and REFINE Investigators. Attenuated recovery of heart rate turbulence early after myocardial infarction identifies patients at high risk for fatal or near-fatal arrhythmic events. Heart Rhythm: The Official Journal of the Heart Rhythm Society. 2010; 7: 229–235.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg J. S., Varma N., Cygankiewicz I. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017; 14(7): 55–96.</mixed-citation><mixed-citation xml:lang="en">Steinberg J. S., Varma N., Cygankiewicz I. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017; 14(7): 55–96.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Макаров Л. М. Холтеровское мониторирование. 4-е изд. М.: Медпрактика-М; 2017: 504.</mixed-citation><mixed-citation xml:lang="en">Makarov L. M. Holter monitoring. 4th edition. Moscow: Medpraktika-M; 2017: 504 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ланг Т. А., Сесик М. Как описывать статистику в медицине. Руководство для авторов, редакторов и рецензентов. М.: Практическая Медицина; 2011: 480.</mixed-citation><mixed-citation xml:lang="en">Lang T. A., Sesik M. How to describe the statistics in medicine. A guide for authors, editors and reviewers. Moscow: Prakticheskaya Medicina; 2011: 480 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zipes D. P., Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm. 2006; 3: 108–113.</mixed-citation><mixed-citation xml:lang="en">Zipes D. P., Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm. 2006; 3: 108–113.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Богова О. Т., Чукаева И. И. Инфаркт миокарда. Воспаление и прогноз. Российский кардиологический журнал. 2003; 4(42): 95–97.</mixed-citation><mixed-citation xml:lang="en">Bogova O. T., Chukaeva I. I. Inflammation and prognosis. Rossijskij kardiologicheskij zhurnal. 2003; 4(42): 95–97 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018; 39(2): 119–177.</mixed-citation><mixed-citation xml:lang="en">2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018; 39(2): 119–177.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P. M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103: 1813–1818.</mixed-citation><mixed-citation xml:lang="en">Ridker P. M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103: 1813–1818.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Королева О. С., Затейщиков Д. А. Биомаркеры в кардиологии: регистрация внутрисосудистого воспаления. Фарматека. 2007; 8(9): 30–36.</mixed-citation><mixed-citation xml:lang="en">Koroleva O. S., Zatejshchikov D. A. Biomarkers in cardiology: registration of intravascular inflammation. Farmateka. 2007; 8(9): 30–36 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Беленькова Ю. А., Кашталап В. В., Каретникова В. Н., Зыков М. В., Барбараш О. Л. Факторы воспаления, влияющие на прогноз у больных инфарктом миокарда с подъемом сегмента ST, подвергшихся чрескожным коронарным вмешательствам. Международный журнал интервенционной кардиоангиологии. 2012; 29: 51–59.</mixed-citation><mixed-citation xml:lang="en">Belen’kova YU. A., Kashtalap V. V., Karetnikova V. N., Zykov M. V., Barbarash O. L. Inflammation factors affecting the prognosis in patients with myocardial infarction with ST-segment elevation undergoing percutaneous coronary interventions. Mezhdunarodnyj zhurnal intervencionnoj kardioangiologii. 2012; 29: 51–59 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Макоева М. Х., Федорова М. М., Автандилов А. Г., Семитко С. П., Долгов В. В., Ройтман А. П. Динамика и прогностическое значение мозгового натрийуретического пептида и С-реактивного белка при остром инфаркте миокарда в зависимости от тактики лечения. Клиническая лабораторная диагностика. 2014; 2: 23–26.</mixed-citation><mixed-citation xml:lang="en">Makoeva M. H., Fedorova M. M., Avtandilov A. G., Semitko S. P., Dolgov V. V., Rojtman A. P. Dynamics and prognostic value of brain natriuretic peptide and C-reactive protein in acute myocardial infarction, depending on the treatment tactics. Klinicheskaya laboratornaya diagnostika. 2014; 2: 23–26 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Darbar D., Davidson N. C., Gillespie N., Choy A. M., Lang C. C., Shyr Y., McNeill G. P., Pringle T. H., Struthers A. D. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am. J. Cardiol. 1996; 78(3): 284–287.</mixed-citation><mixed-citation xml:lang="en">Darbar D., Davidson N. C., Gillespie N., Choy A. M., Lang C. C., Shyr Y., McNeill G. P., Pringle T. H., Struthers A. D. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am. J. Cardiol. 1996; 78(3): 284–287.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Patton K. K., Sotoodehnia N., DeFilippi C., Siscovick D. S., Gottdiener J. S., Kronmal R. A. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm. 2011; 8(2): 228–233.</mixed-citation><mixed-citation xml:lang="en">Patton K. K., Sotoodehnia N., DeFilippi C., Siscovick D. S., Gottdiener J. S., Kronmal R. A. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm. 2011; 8(2): 228–233.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Александрова Е. Б., Сидоренко Б. А. Мозговой натрийуретический пептид в ранней диагностике хронической сердечной недостаточности у пациентов с сохраненной фракцией выброса левого желудочка. Кардиология. 2012; 52(11): 27–32.</mixed-citation><mixed-citation xml:lang="en">Aleksandrova E. B., Sidorenko B. A. Brain natriuretic peptide in the early diagnosis of chronic heart failure in patients with preserved left ventricular ejection fraction. Kardiologiya. 2012; 52(11): 27–32 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Leto L., Testa M., Feola M. The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NTproBNP. Minerva Cardioangiol. 2016; 64(2): 157–164.</mixed-citation><mixed-citation xml:lang="en">Leto L., Testa M., Feola M. The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NTproBNP. Minerva Cardioangiol. 2016; 64(2): 157–164.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Richards A. M. The relationship of plasma NT-proBNP to age and outcomes in heart failure. JACC Heart Fail. 2016; 4(9): 746–748.</mixed-citation><mixed-citation xml:lang="en">Richards A. M. The relationship of plasma NT-proBNP to age and outcomes in heart failure. JACC Heart Fail. 2016; 4(9): 746–748.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
